Integration and bioinformatics analysis of DNA‑methylated genes associated with drug resistance in ovarian cancer
- Authors:
- Bingbing Yan
- Fuqiang Yin
- Qi Wang
- Wei Zhang
- Li Li
-
Affiliations: Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Medical Scientific Research Centre, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China - Published online on: May 18, 2016 https://doi.org/10.3892/ol.2016.4608
- Pages: 157-166
This article is mentioned in:
Abstract
Cho KR and Shih IeM: Ovarian cancer. Annu Rev Pathol. 4:287–313. 2009. View Article : Google Scholar : PubMed/NCBI | |
Balch C, Huang TH, Brown R and Nephew KP: The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol. 191:1552–1572. 2004. View Article : Google Scholar : PubMed/NCBI | |
Novik KL, Nimmrich I, Genc B, Maier S, Piepenbrock C, Olek A and Beck S: Epigenomics: genome-wide study of methylation phenomena. Curr Issues Mol Biol. 4:111–28. 2002.PubMed/NCBI | |
Lund AH and van Lohuizen M: Epigenetics and cancer. Genes Dev. 18:2315–2335. 2004. View Article : Google Scholar : PubMed/NCBI | |
Seeber LM and van Diest PJ: Epigenetics in ovarian cancer. Methods Mol Biol. 863:253–69. 2012. View Article : Google Scholar : PubMed/NCBI | |
Widschwendter M, Jiang G, Woods C, Müller HM, Fiegl H, Goebel G, Marth C, Müller-Holzner E, Zeimet AG, Laird PW and Ehrlich M: DNA hypomethylation and ovarian cancer biology. Cancer Res. 64:4472–4480. 2004. View Article : Google Scholar : PubMed/NCBI | |
Zhang B, Kirov S and Snoddy J: WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 33(Web Server issue): W741–W748. 2005. View Article : Google Scholar : PubMed/NCBI | |
Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C and Jensen LJ: STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41(Database issue): D808–D815. 2013. View Article : Google Scholar : PubMed/NCBI | |
Eyre R, Harvey I, Stemke-Hale K, Lennard TW, Tyson-Capper A and Meeson AP: Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population. Tumour Biol. 35:9879–9892. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hatle KM, Neveu W, Dienz O, Rymarchyk S, Barrantes R, Hale S, Farley N, Lounsbury KM, Bond JP, Taatjes D and Rincón M: Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression. Mol Cell Biol. 27:2952–66. 2007. View Article : Google Scholar : PubMed/NCBI | |
Lee PS, Teaberry VS, Bland AE, et al: Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Int J Cancer. 126:1378–1389. 2010.PubMed/NCBI | |
Harvey I, Stemke-Hale K, Lennard TW, Tyson-Capper A and Meeson AP: Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population. Tumour Biol. 35:9879–9892. 2014. View Article : Google Scholar : PubMed/NCBI | |
Watanabe Y, Ueda H, Etoh T, Koike E, Fujinami N, Mitsuhashi A and Hoshiai H: A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer. Anticancer Res. 27:1449–1452. 2007.PubMed/NCBI | |
Gifford G, Paul J, Vasey PA, Kaye SB and Brown R: The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 10:4420–4426. 2004. View Article : Google Scholar : PubMed/NCBI | |
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI | |
Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, et al: BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol. 7:567–579. 2013. View Article : Google Scholar : PubMed/NCBI | |
Wang YQ, Zhang JR, Li SD, He YY, Yang YX, Liu XL and Wan XP: Aberrant methylation of breast and ovarian cancer susceptibility gene 1 in chemosensitive human ovarian cancer cells does not involve the phosphatidylinositol 3′-kinase-Akt pathway. Cancer Sci. 101:1618–1623. 2010. View Article : Google Scholar : PubMed/NCBI | |
Chou JL, Su HY, Chen LY, Liao YP, Hartman-Frey C, Lai YH, Yang HW, Deatherage DE, Kuo CT, Huang YW, et al: Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest. 90:414–25. 2010. View Article : Google Scholar : PubMed/NCBI | |
Strathdee G, Vass JK, Oien KA, Siddiqui N, Curto-Garcia J and Brown R: Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol. 97:898–903. 2005. View Article : Google Scholar : PubMed/NCBI | |
Strathdee G, Davies BR, Vass JK, Siddiqui N and Brown R: Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene. Carcinogenesis. 25:693–701. 2004. View Article : Google Scholar : PubMed/NCBI | |
Yao X, Hu JF, Li T, Yang Y, Sun Z, Ulaner GA, Vu TH and Hoffman AR: Epigenetic regulation of the taxol resistance-associated gene TRAG-3 in human tumors. Cancer Genet Cytogenet. 151:1–13. 2004. View Article : Google Scholar : PubMed/NCBI | |
Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, et al: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 28:209–218. 2009. View Article : Google Scholar : PubMed/NCBI | |
Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, Koensgen D, Mustea A, Schmid P and Crook T: Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer. 125:1454–1463. 2009. View Article : Google Scholar : PubMed/NCBI | |
Vos MD, Martinez A, Elam C, Dallol A, Taylor BJ, Latif F and Clark GJ: A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res. 64:4244–4250. 2004. View Article : Google Scholar : PubMed/NCBI | |
Kassler S, Donninger H, Birrer MJ and Clark GJ: RASSF1A and the Taxol response in ovarian cancer. Mol Biol Int. 2012:2632672012. View Article : Google Scholar : PubMed/NCBI | |
Blanco-Aparicio C, Renner O, Leal JF and Carnero A: PTEN, more than the AKT pathway. Carcinogenesis. 28:1379–1386. 2007. View Article : Google Scholar : PubMed/NCBI | |
Dai F, Zhang Y, Zhu X, Shan N and Chen Y: Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation. Target Oncol. 7:217–225. 2012. View Article : Google Scholar : PubMed/NCBI | |
Horak P, Pils D, Haller G, Pribill I, Roessler M, Tomek S, Horvat R, Zeillinger R, Zielinski C and Krainer M: Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res. 3:335–343. 2005. View Article : Google Scholar : PubMed/NCBI | |
Li Y, Hu W, Shen DY, Kavanagh JJ and Fu S: Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol. 200(177): e1–e9. 2009. | |
Bram EE, Hu W, Shen DY, Kavanagh JJ and Fu S: Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia. 11:1359–1370. 2009. View Article : Google Scholar : PubMed/NCBI | |
Park ST, Byun HJ, Kim BR, Dong SM, Park SH, Jang PR and Rho S: Tumor suppressor BLU promotes paclitaxel antitumor activity by inducing apoptosis through the down-regulation of Bcl-2 expression in tumorigenesis. Biochem Biophys Res Commun. 435:153–159. 2013. View Article : Google Scholar : PubMed/NCBI | |
Chiang YC, Chang MC, Chen PJ, Wu MM, Hsieh CY, Cheng WF and Chen CA: Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients. Endocr Relat Cancer. 20:213–227. 2013. View Article : Google Scholar : PubMed/NCBI | |
Wang N, Zhang H, Yao Q, Wang Y, Dai S and Yang X: TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer. J Exp Clin Cancer Res. 31:62012. View Article : Google Scholar : PubMed/NCBI | |
Ali MW, Cacan E, Liu Y, Pierce JY, Creasman WT, Murph MM, Govindarajan R, Eblen ST, Greer SF and Hooks SB: Transcriptional suppression, DNA methylation and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells. PLoS One. 8:e601852013. View Article : Google Scholar : PubMed/NCBI | |
Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T and Ushijima T: Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer. 119:1338–1344. 2006. View Article : Google Scholar : PubMed/NCBI | |
Jin C, Yu W, Lou X, Zhou F, Han X, Zhao N and Lin B: UCHL1 is a putative tumor suppressor in ovarian cancer cells and contributes to cisplatin resistance. J Cancer. 4:662–670. 2013. View Article : Google Scholar : PubMed/NCBI | |
He X, Khurana A, Roy D, Kaufmann S and Shridhar V: Loss of HSulf-1 expression enhances tumorigenicity by inhibiting Bim expression in ovarian cancer. Int J Cancer. 135:1783–1789. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR and Shridhar V: Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem. 278:23107–23117. 2003. View Article : Google Scholar : PubMed/NCBI | |
Su HY, Lai HC, Lin YW, Liu CY, Chen CK, Chou YC, Lin SP, Lin WC, Lee HY and Yu MH: Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer. 127:555–567. 2010. View Article : Google Scholar : PubMed/NCBI | |
Gao S, Zhao X, Lin B, Hu Z, Yan L and Gao J: Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance. Tumour Biol. 33:1759–1765. 2012. View Article : Google Scholar : PubMed/NCBI | |
Izutsu N, Maesawa C, Shibazaki M, Oikawa H, Shoji T, Sugiyama T and Masuda T: Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells. Int J Oncol. 32:1227–1235. 2008.PubMed/NCBI | |
Pattamadilok J, Huapai N, Rattanatanyong P, Vasurattana A, Triratanachat S, Tresukosol D and Mutirangura A: LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer. 18:711–717. 2008. View Article : Google Scholar : PubMed/NCBI | |
Litkouhi B, Kwong J, Lo CM, Smedley JG III, McClane BA, Aponte M, Gao Z, Sarno JL, Hinners J, Welch WR, et al: Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia. 9:304–314. 2007. View Article : Google Scholar : PubMed/NCBI | |
Lin X, Shang X, Manorek G and Howell SB: Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4. PLoS One. 8:e674962013. View Article : Google Scholar : PubMed/NCBI | |
Shang X, Lin X, Alvarez E, Manorek G and Howell SB: Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia. 14:974–985. 2012. View Article : Google Scholar : PubMed/NCBI | |
Shang X, Lin X, Manorek G and Howell SB: Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Mol Pharmacol. 83:85–94. 2013. View Article : Google Scholar : PubMed/NCBI | |
Jiang Y, Chu Y, Tang W, Wan Y, Zhang L and Cheng W: Transcription factor WT1 and promoter CpG hypomethylation coactivate HOXA10 expression in ovarian cancer. Curr Pharm Des. 20:1647–1654. 2014. View Article : Google Scholar : PubMed/NCBI | |
Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T and Nephew KP: Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 72:2197–2205. 2012. View Article : Google Scholar : PubMed/NCBI | |
Li B, Jin H, Yu Y, Gu C, Zhou X, Zhao N and Feng Y: HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival. Int J Gynecol Cancer. 19:1347–1352. 2009. View Article : Google Scholar : PubMed/NCBI | |
Widschwendter M, Apostolidou S, Jones AA, Fourkala EO, Arora R, Pearce CL, Frasco MA, Ayhan A, Zikan M, Cibula D, et al: HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study. Int J Cancer. 125:2214–2218. 2009. View Article : Google Scholar : PubMed/NCBI | |
Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ and Widschwendter M: HOXA11 DNA methylation - a novel prognostic biomarker in ovarian cancer. Int J Cancer. 123:725–729. 2008. View Article : Google Scholar : PubMed/NCBI | |
Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC and D'Andrea AD: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 9:568–574. 2003. View Article : Google Scholar : PubMed/NCBI | |
Cai J, Xu L, Tang H, Yang Q, Yi X, Fang Y, Zhu Y and Wang Z: The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis. Oncologist. 19:528–535. 2014. View Article : Google Scholar : PubMed/NCBI | |
Chu EC and Tarnawski AS: PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit. 10:RA235–RA241. 2004.PubMed/NCBI | |
Lee S, Choi EJ, Jin C and Kim DH: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI | |
Wu H, Cao Y, Weng D, Xing H, Song X, Zhou J, Xu G, Lu Y, Wang S and Ma D: Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett. 271:260–271. 2008. View Article : Google Scholar : PubMed/NCBI | |
Sui H, Fan ZZ and Li Q: Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res. 40:426–435. 2012. View Article : Google Scholar : PubMed/NCBI | |
Krishnamurthy P and Schuetz JD: Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol. 46:381–410. 2006. View Article : Google Scholar : PubMed/NCBI | |
Chen Y, Bieber MM and Teng NN: Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer. Mol Carcinog. 53:625–634. 2014.PubMed/NCBI | |
Schneider J, Jimenez E, Marenbach K, Marx D and Meden H: Co-expression of the MDR1 gene and HSP27 in human ovarian cancer. Anticancer Res. 18:2967–2971. 1998.PubMed/NCBI | |
Yang HJ, Liu VW, Wang Y, Tsang PC and Ngan HY: Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer. 6:2122006. View Article : Google Scholar : PubMed/NCBI | |
Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA and Welcsh P: Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer. 8:482009. View Article : Google Scholar : PubMed/NCBI | |
Kang S, Dong SM and Park NH: Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer. Gynecol Oncol. 118:58–63. 2010. View Article : Google Scholar : PubMed/NCBI | |
Ignatov T, Eggemann H, Costa SD, Roessner A, Kalinski T and Ignatov A: BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer. J Cancer Res Clin Oncol. 140:1457–1463. 2014. View Article : Google Scholar : PubMed/NCBI | |
de Ibanez Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL and Cairns P: Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma and peritoneal fluid from ovarian cancer patients. Cancer Res. 64:6476–6481. 2004. View Article : Google Scholar : PubMed/NCBI | |
Zhang H, Zhang S, Cui J, Zhang A, Shen L and Yu H: Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer. Aust N Z J Obstet Gynaecol. 48:505–509. 2008. View Article : Google Scholar : PubMed/NCBI | |
Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP and Matei DE: A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer. 116:4043–4053. 2010. View Article : Google Scholar : PubMed/NCBI | |
Bhagat R, Chadaga S, Premalata CS, Ramesh G, Ramesh C, Pallavi VR and Krishnamoorthy L: Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development. Cell Oncol (Dordr). 35:473–479. 2012. View Article : Google Scholar : PubMed/NCBI | |
Bondurant AE, Huang Z, Whitaker RS, Simel LR, Berchuck A and Murphy SK: Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. Gynecol Oncol. 123:581–587. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ma L, Zhang JH, Liu FR and Zhang X: Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors. Zhonghua Zhong Liu Za Zhi. 27:657–659. 2005.(In Chinese). PubMed/NCBI | |
Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, Kamat A, Sood AK and Levenson V: Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol. 120:113–120. 2011. View Article : Google Scholar : PubMed/NCBI | |
Shen Y, Shen R, Ge L, Zhu Q and Li F: Fibrillar type I collagen matrices enhance metastasis/invasion of ovarian epithelial cancer via β1 integrin and PTEN signals. Int J Gynecol Cancer. 22:1316–1324. 2012. View Article : Google Scholar : PubMed/NCBI | |
Qiao YH, Cheng J and Guo RX: Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer. Zhonghua Fu Chan Ke Za Zhi. 42:325–329. 2007.(In Chinese). PubMed/NCBI | |
Che Y, Yao Q, Dai S, Luo B and Wang Y: Study of the mutation and expression of PTEN gene in endometrial carcinoma and epithelial ovarian cancer. Zhonghua Fu Chan Ke Za Zhi. 37:608–611. 2002.(In Chinese). PubMed/NCBI | |
Dong HP, Kleinberg L, Silins I, Flørenes VA, Tropé CG, Risberg B, Nesland JM and Davidson B: Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer. 112:84–93. 2008. View Article : Google Scholar : PubMed/NCBI | |
Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, et al: Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 117:1661–1669. 2011. View Article : Google Scholar : PubMed/NCBI | |
Brait M, Maldonado L, Noordhuis MG, Begum S, Loyo M, Poeta ML, Barbosa A, Fazio VM, Angioli R, Rabitti C, et al: Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression. PLoS One. 8:e708782013. View Article : Google Scholar : PubMed/NCBI | |
Al-Shabanah OA, Hafez MM, Hassan ZK, Sayed-Ahmed MM, Abozeed WN, Alsheikh A and Al-Rejaie SS: Methylation of SFRPs and APC genes in ovarian cancer infected with high risk human papillomavirus. Asian Pac J Cancer Prev. 15:2719–2725. 2014. View Article : Google Scholar : PubMed/NCBI | |
Saran U, Arfuso F, Zeps N and Dharmarajan A: Secreted frizzled-related protein 4 expression is positively associated with responsiveness to cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers. BMC Cell Biol. 13:252012. View Article : Google Scholar : PubMed/NCBI | |
Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, et al: Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res. 15:2448–2455. 2009. View Article : Google Scholar : PubMed/NCBI | |
Raspaglio G, Petrillo M, Martinelli E, Li Puma DD, Mariani M, De Donato M, Filippetti F, Mozzetti S, Prislei S, Zannoni GF, et al: Sox9 and Hif-2α regulate TUBB3 gene expression and affect ovarian cancer aggressiveness. Gene. 542:173–181. 2014. View Article : Google Scholar : PubMed/NCBI | |
Tanwar PS, Kaneko-Tarui T, Lee HJ, Zhang L and Teixeira JM: PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression. Carcinogenesis. 34:893–901. 2013. View Article : Google Scholar : PubMed/NCBI | |
Dhillon VS, Shahid M and Husain SA: CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer. 3:332004. View Article : Google Scholar : PubMed/NCBI | |
Materna V, Surowiak P, Kaplenko I, Spaczyński M, Duan Z, Zabel M, Dietel M and Lage H: Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients. Virchows Arch. 450:187–194. 2007. View Article : Google Scholar : PubMed/NCBI | |
Su HY, Lai HC, Lin YW, Chou YC, Liu CY and Yu MH: An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer. 124:387–393. 2009. View Article : Google Scholar : PubMed/NCBI | |
Lum E, Vigliotti M, Banerjee N, Cutter N, Wrzeszczynski KO, Khan S, Kamalakaran S, Levine DA, Dimitrova N and Lucito R: Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis. Gynecol Oncol. 130:369–376. 2013. View Article : Google Scholar : PubMed/NCBI | |
Karaca B, Atmaca H, Bozkurt E, Kisim A, Uzunoglu S, Karabulut B, Sezgin C, Sanli UA and Uslu R: Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells. Mol Biol Rep. 40:3925–3933. 2013. View Article : Google Scholar : PubMed/NCBI | |
Lawen A: Apoptosis - an introduction. Bioessays. 25:888–896. 2003. View Article : Google Scholar : PubMed/NCBI | |
Singh M, Chaudhry P, Fabi F and Asselin E: Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance. BMC Cancer. 13:2332013. View Article : Google Scholar : PubMed/NCBI | |
Strathdee G, MacKean MJ, Illand M and Brown R: A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 18:2335–2341. 1999. View Article : Google Scholar : PubMed/NCBI |